COMPANY

LeonaBio

HQ: Bothell, WA source · leonabio.com ↗ · West Coast

6 open jobs · last seen Oct 23, 2026 · 10 sources

Keywords: small molecule Alzheimer Disease Dementia of Alzheimer Type Metastatic Breast Cancer Parkinson Disease Dementia Dementia With Lewy Bodies ATH-1017 ATH-1105 ATH-1020 NDX-1017

Location: Bothell, WA · source · Oct 14, 2026

Profile checked Oct 10, 2026

6Open jobs 9Trials (company is sponsor)

Hiring

Title	Location (from posting)	Employer posted	First seen
Sr. Scientist - Oncology Research	Bothell, Washington	Not stated	Oct 11, 2026
Senior Director, Medical Affairs	Bothell, Washington, United States	Not stated	Oct 11, 2026
Director, Regulatory Affairs, Strategy	Bothell, Washington, United States	Not stated	Oct 11, 2026
Director, Drug Safety	Bothell, Washington, United States	Not stated	Oct 11, 2026
Sr. Director, Biostatistics	Bothell, Washington, United States	Not stated	Oct 11, 2026

See all 6 jobs

Timeline

Dec 18, 2025 Partnership Partnership / licensing: $90M (upfront, as published), announced Dec 18, 2025. Source: SEC filing. source ↗
Apr 24, 2024 Trial start Phase 1: A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105 source ↗
Oct 31, 2023 Trial start Phase 3: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation source ↗
Jul 13, 2022 Trial start Phase 1: A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017) source ↗
Mar 30, 2022 Trial start Phase 1: Safety, Tolerability, and Pharmacokinetics Study of ATH-1020 source ↗
Jan 20, 2022 Trial start Phase 2: ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial) source ↗
Jun 30, 2021 Trial start Phase 2/Phase 3: Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease source ↗
Nov 23, 2020 Trial start Phase 2: A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease source ↗
Sep 28, 2020 Trial start Phase 2/Phase 3: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease source ↗
Oct 9, 2017 Trial start Phase 1: Safety, Tolerability, and Pharmacokinetics Study of NDX-1017 source ↗

Upcoming milestones

2027-04 (ESTIMATED) · Phase 3 · Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation · NCT05696626

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Dec 18, 2025 Partnership / licensing: $90M (upfront, as published), announced Dec 18, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 9

Record	Title	Phase	Status	Start	Primary completion
NCT05696626	Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation	Phase 3	Recruiting	Oct 31, 2023	2027-04 (estimated)
NCT04488419	ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease	Phase 2/Phase 3	Completed	Sep 28, 2020	Jul 15, 2024 (actual)
NCT04886063	Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease	Phase 2/Phase 3	Terminated	Jun 30, 2021	Oct 23, 2024 (actual)
NCT04831281	ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)	Phase 2	Terminated	Jan 20, 2022	Apr 19, 2023 (actual)
NCT06432647	A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105	Phase 1	Completed	Apr 24, 2024	Nov 25, 2024 (actual)
NCT05169671	Safety, Tolerability, and Pharmacokinetics Study of ATH-1020	Phase 1	Completed	Mar 30, 2022	Sep 9, 2022 (actual)
NCT04491006	A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease	Phase 2	Completed	Nov 23, 2020	May 20, 2022 (actual)
NCT05511558	A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017)	Phase 1	Completed	Jul 13, 2022	Oct 18, 2022 (actual)
NCT03298672	Safety, Tolerability, and Pharmacokinetics Study of NDX-1017	Phase 1	Completed	Oct 9, 2017	Sep 5, 2019 (actual)

Open jobs 6

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Sr. Scientist - Oncology Research	Bothell, Washington	Not stated	Oct 11, 2026	Senior
Senior Director, Medical Affairs	Bothell, Washington, United States	Not stated	Oct 11, 2026	Senior
Director, Regulatory Affairs, Strategy	Bothell, Washington, United States	Not stated	Oct 11, 2026	Senior
Director, Drug Safety	Bothell, Washington, United States	Not stated	Oct 11, 2026	Senior
Sr. Director, Biostatistics	Bothell, Washington, United States	Not stated	Oct 11, 2026	Senior
Vice President, Quality	Bothell, Washington, United States	Not stated	Oct 11, 2026	Executive

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.